| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Operating Activities | ||||||
Net Loss | ||||||
-43,285 | -26,478 | -9,133 | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | ||||||
2,842 | 1,141 | 207 | ||||
Stock-based consideration in connection with acquisition of product rights (Note 5) | ||||||
- | 3,978 | 3,400 | ||||
Change in fair value of warrant liability | ||||||
- | 520 | 125 | ||||
Amortization of premium and discounts on marketable securities | ||||||
16 | - | - | ||||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
-2,367 | 2,396 | 469 | ||||
Accounts payable | ||||||
1,207 | 109 | 459 | ||||
Accrued interest recievable | ||||||
-58 | - | - | ||||
Accrued expenses | ||||||
762 | 484 | 529 | ||||
Net cash used in operating activities | ||||||
-36,065 | -22,642 | -4,882 | ||||
Investing activities | ||||||
Purchase of marketable securities | ||||||
46,250 | - | - | ||||
Net cash provided by in investing activities | ||||||
-46,250 | - | - | ||||
Financing activities | ||||||
Proceeds from underwritten public offering, net | ||||||
42,651 | - | - | ||||
Issuance of common stock in connection with private placement with Amgen | ||||||
20,000 | - | - | ||||
Proceeds from initial public offering, net | ||||||
- | 59,322 | - | ||||
Proceeds from issuance of Series A Convertible Redeemable Preferred Stock, net | ||||||
- | - | 26,715 | ||||
Proceeds from issuance of common stock | ||||||
290 | 25 | 1 | ||||
Net cash provided by financing activities | ||||||
62,941 | 59,347 | 26,716 | ||||
Net decrease in cash and cash equivalents | ||||||
-19,374 | 36,705 | 21,834 | ||||
Supplemental disclosure of non-cash financing transactions: | ||||||
Conversion of Series A Preferred Stock to common stock upon completion of IPO | ||||||
- | 26,461 | - | ||||
Reclassification of Series A Preferred Stock warrant liability to stockholders' equity | ||||||
- | 1,518 | - | ||||
Fair value of warrant issued in connection with Series A Convertible Redeemable Preferred Stock | ||||||
- | - | 873 | ||||
Accretion of Series A Convertible Redeemable Preferred Stock | ||||||
- | 276 | 343 | ||||